<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127218</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00035188</org_study_id>
    <secondary_id>5R01AG021570-03</secondary_id>
    <nct_id>NCT00127218</nct_id>
  </id_info>
  <brief_title>High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly</brief_title>
  <acronym>NIA-Plaque</acronym>
  <official_title>HDL Increased Plaque Stabilization in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the added benefits of increased high-density
      lipoprotein (HDL) cholesterol serum levels over and above those achieved by lipid lowering
      therapy guided by current guidelines, in older individuals with cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis being tested is that the current standard lipid lowering therapy, combined
      with a 20 percent or greater increase in serum HDL induced by long-acting niacin, reduces
      plaque size in older individuals with cardiovascular disease. The specific aims of testing
      this hypothesis are:

        1. to determine the effects of statin plus placebo vs. statin plus niacin therapy on plaque
           size and composition,

        2. to determine whether alterations of inflammatory markers of atherosclerosis induced by
           lipid lowering therapy parallel alterations of plaque architecture and composition in
           older patients with cardiovascular disease,

        3. to determine the effects of these interventions on the incidence of cardiovascular and
           cerebrovascular events.

      The results of the trial will be directly applicable to developing strategies for plaque
      stabilization in the elderly who suffer the most from the severe complications of advanced
      cardiovascular atherosclerosis.

      A total of 144 participants aged 65 and older with cardiovascular or cerebrovascular disease
      will be recruited. Participants will be randomized to receive either statin plus niacin or
      statin plus a placebo for 18 months. Participants will be provided a prescription for
      fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any
      other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily,
      atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily. Ten visits are expected,
      initially every 4 weeks for dose adjustment. Then visits will be every 6 months; MRI,
      Inflammatory Markers tests, and other lab tests will be done at baseline and the visits at
      months 6, 12, and 18.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries</measure>
    <time_frame>18 months</time_frame>
    <description>The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)</measure>
    <time_frame>18 months</time_frame>
    <description>Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>any statin plus niacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>any statin plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>any statin</intervention_name>
    <description>Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>fluvastatin (Lescol)</other_name>
    <other_name>pravastatin (Pravachol)</other_name>
    <other_name>simvastatin (Vytorin)</other_name>
    <other_name>atorvastatin (Lipitor)</other_name>
    <other_name>rosuvastatin (Crestor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin</intervention_name>
    <description>long-acting niacin daily for 18 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo pill daily for 18 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 65 or older

          -  Documented clinical cardiovascular or cerebrovascular disease due to atherosclerosis

          -  Candidate for lipid lowering therapy; no contraindication to fluvastatin, niacin or
             aspirin therapy

          -  Low-density lipoprotein (LDL) cholesterol below 150 mg/dl if untreated or below 125
             mg/dl on statin monotherapy

          -  Willing to discontinue present therapy if private physician agrees with enrollment

          -  Eligible to undergo trans-esophageal magnetic resonance imaging (MRI); no
             contraindications to Gadolinium-DTPA, the contrast agent used

          -  Willing to sign Informed Consent

        Exclusion Criteria:

          -  Ineligibility for MRI procedure due to pacemaker, metal implants, or other
             ferromagnetic devices

          -  Claustrophobia

          -  Previously documented esophageal disease which would preclude trans-esophageal MRI

          -  LDL-C greater than 150 mg/dl off lipid lowering therapy or daily statin therapy
             requiring doses greater than 20 mg of atorvastatin, 20 mg of simvastatin, 80 mg of
             lovastatin, 80 mg of pravastatin, 80 mg of extended release fluvastatin, or 20 mg of
             rosuvastatin

          -  Contraindication or allergy to statins or aspirin

          -  Current use of or known intolerance or allergy to Niaspan (a long-acting niacin)

          -  Allergy or intolerance to Gadolinium-DTPA (MRI contrast agent)

          -  Liver or kidney failure defined clinically and by laboratory data

          -  Mental, neurologic or social condition preventing understanding of the rationale,
             procedures, risks and potential benefits associated with the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joao AC Lima, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Unversity School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998 Sep 15;82(6):737-43.</citation>
    <PMID>9761083</PMID>
  </reference>
  <reference>
    <citation>Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, Gotto AM Jr. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999 Feb 16;99(6):736-43.</citation>
    <PMID>9989957</PMID>
  </reference>
  <reference>
    <citation>Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 Nov 29;345(22):1583-92.</citation>
    <PMID>11757504</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <results_first_submitted>September 1, 2015</results_first_submitted>
  <results_first_submitted_qc>October 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2015</results_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atherosclerotic plaque</keyword>
  <keyword>MRI</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>statins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Fluvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized in a 1:1 ratio to receive niacin or placebo, using a random number schema stratiﬁed to ensure equal numbers between age 65–74 years and 75 years and above. Study took place in a university outpatient center.</recruitment_details>
      <pre_assignment_details>Participants were over age 65 years with a history of cardiovascular events or evidence of atherosclerosis at angiography (&gt;50% stenosis) or non-invasive imaging, with baseline LDL&lt;3.24 mmol/L if already on statin therapy and &lt;3.89 mmol/L if untreated. There were no restrictions on HDL level.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Niacin Plus Statin</title>
          <description>Extended release niacin (1500 mg daily) plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
        </group>
        <group group_id="P2">
          <title>Placebo Plus Statin</title>
          <description>placebo plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Niacin Plus Statin</title>
          <description>Extended release niacin (1500 mg daily) plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
        </group>
        <group group_id="B2">
          <title>Placebo Plus Statin</title>
          <description>placebo plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="69" upper_limit="77"/>
                    <measurement group_id="B2" value="72" lower_limit="69" upper_limit="77"/>
                    <measurement group_id="B3" value="73" lower_limit="69" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries</title>
        <description>The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Niacin Plus Statin</title>
            <description>Extended release niacin (1500 mg daily) plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Statin</title>
            <description>placebo plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries</title>
          <description>The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries.</description>
          <units>percentage of internal carotid artery</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread=".2"/>
                    <measurement group_id="O2" value="5" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)</title>
        <description>Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded</description>
        <time_frame>18 months</time_frame>
        <population>Cardiovascular event (stroke) was seen in only 1 patient and 5 patients needed myocardial revascularization</population>
        <group_list>
          <group group_id="O1">
            <title>Any Statin Plus Niacin</title>
            <description>any statin plus niacin
any statin: Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
niacin: long-acting niacin daily for 18 months</description>
          </group>
          <group group_id="O2">
            <title>Any Statin Plus Placebo</title>
            <description>any statin plus placebo
any statin: Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
Placebo: matching placebo pill daily for 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)</title>
          <description>Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded</description>
          <population>Cardiovascular event (stroke) was seen in only 1 patient and 5 patients needed myocardial revascularization</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Niacin Plus Statin</title>
          <description>Extended release niacin (1500 mg daily) plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus Statin</title>
          <description>placebo plus statin therapy to reach their National Cholesterol Education Program-deﬁned low density lipoprotein (LDL)cholesterol target</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Revascularization</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joao AC Lima</name_or_title>
      <organization>The Johns Hopkins Hospital, Department of Medicine, Division of Cardiology</organization>
      <phone>410-614-1284</phone>
      <email>jlima@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

